Metastatic Melanoma Patient–Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition-Reference-Cited by-同舟云学术

Metastatic Melanoma Patient–Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition

Published:2020-03-31 Issue:14 Volume:26 Page:3803-3818
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Shattuck-Brandt Rebecca L.^ORCID,Chen Sheau-Chiann^ORCID,Murray Emily,Johnson Christopher Andrew,Crandall Holly,O'Neal Jamye F.,Al-Rohil Rami Nayef^ORCID,Nebhan Caroline A.,Bharti Vijaya^ORCID,Dahlman Kimberly B.,Ayers Gregory D.,Yan Chi,Kelley Mark C.,Kauffmann Rondi M.,Hooks Mary,Grau Ana,Johnson Douglas B.,Vilgelm Anna E.,Richmond Ann^ORCID

Funder

NCINIHNIH

Vanderbilt Mouse Metabolic Phenotyping Center

NCI

Vanderbilt-Ingram Cancer Center

James C. Bradford Jr. Melanoma Fund

BCRF

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Amelanotic primary cervical malignant melanoma: A case report and review of literature;World Journal of Clinical Oncology;2024-07-24

2. MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future;Pharmacological Reviews;2024-03-15

3. Salvianolic Acid B Significantly Suppresses the Migration of Melanoma Cells via Direct Interaction with β-Actin;Molecules;2024-02-19

4. Advancements in MDM2 inhibition: Clinical and pre-clinical investigations of combination therapeutic regimens;Saudi Pharmaceutical Journal;2023-10

5. Generation of Orthotopic Patient-Derived Xenografts in Humanized Mice for Evaluation of Emerging Targeted Therapies and Immunotherapy Combinations for Melanoma;Cancers;2023-07-20